Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Alivus Life Sciences Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹720
Per ShareLot Size
20 Shares
Minimum Investment
₹14,400
Issue Size
₹1,497.85 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
100%
Issue Type
Book Building
ISIN
INE03Q201024
Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients ("APIs") in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes. The Company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. It is also increasingly providing contract development and manufacturing operations ("CDMO") services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It is a research and development ("R&D")-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where it believes there is growth potential in the future.
The global API market was estimated to be around US$181.3 billion in FY 2020 and is expected to grow at a CAGR of 6.2% to reach to about US$259.3 billion by FY 2026. The Indian API industry has been on a high growth trajectory over the past few decades. The Indian bulk drug industry, ranked third in the world, has grown at a CAGR of around 9% over FY 2016-2020. It is further expected to expand and grow at a CAGR of around 9.6% during FY 2021-2026, signifying its future potential and evolving global importance. The API supply chain is shaped by changing demand in the pharmaceutical industry, with price and regulatory enforcement being two of the most significant drivers of change.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offer of 21,022,222 equity shares of face value of Rs. 2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of Rs. 720 per equity share (including a share premium of Rs. 718 per equity share) aggregating to Rs. 1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to Rs. 1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to Rs. 453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company. The face value of equity shares is Rs. 2 each. Offer Price : Rs. 720 per Equity Share of face value of Rs. 2 each. Anchor Investor offer price: Rs. 720 per Equity share. The Offer Price is 360 times the face value.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Glenmark Life Sciences Limited was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ("RoC"). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited' pursuant to a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC.
Glenmark, Teva Pharmaceutical Industries, Torrent Pharmaceuticals, Aurobindo Pharma, Krka and another company which is a global leader in generic pharmaceuticals and biosimilars.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.